Claims for Patent: 6,911,455

Summary for Patent: 6,911,455

Title:	Methods for preparing pharmaceutical formulations
Abstract:	The invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations of histamine releasers. The present invention provides methods for determining the concentration of physiologically acceptable excipients for use in the formulations of the invention. The present invention also provides methods for suppressing pharmaceutically-induced histamine release by administering to an animal, the formulations of the present invention. A kit useful for preparing pharmaceutical formulations of histamine releasers is also provided.
Inventor(s):	Floyd; Alison G. (Durham, NC), Hashim; Mir A (Durham, NC), Lin; Peiyuan (Durham, NC), Mook; Robert A. (Durham, NC), Sefler; Andrea (Durham, NC), Meserve; Kathleen Cornell (Durham, NC), Ricciarelli; Patricia Neal (Durham, NC), Spitzer; Timothy David (Durham, NC)
Assignee:	SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:	10/149,722
Patent Claims:	1. A method for preparing a pharmaceutical formulation containing a histamine releaser and a physiologically acceptable excipient, said method comprising combining a therapeutically effective amount of said histamine releaser with a concentration of the physiologically acceptable excipient; wherein said concentration of the physiologically acceptable excipient, when combined in an aqueous solution with the histamine releaser at or above critical micelle concentration, is sufficient to reduce aggregation of the histamine releaser in the aqueous solution by at least about 25 percent compared to aggregation of the histamine releaser in the aqueous solution containing substantially no physiologically acceptable excipient; wherein the histamine releaser is (Z)-2-chloror-1-{(3-{(1R, 2S)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4 -tetrahydro-2-isoquinolinio}propyl}-4-{3-[(1S, 2R)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-1,2,3,4 -tetrahydro-2-isoquinolinio]propyl}-2-butenedioate dichloride or a pharmaceutically acceptable salt thereof, and the physiologically acceptable excipient is selected from the group consisting of divalent inorganic salts, organic carboxylic acids, phosphoric acid, amino acids, chelating agents, albumins and combinations thereof. 2. The method according to claim 1, wherein the histamine releaser is a neuromuscular blocker. 3. The method according to claim 1, wherein the physiologically acceptable excipient is selected from the group consisting of calcium chloride, sodium sulfate, magnesium sulfate, tartaric acid, maleic acid, acetic acid, citric acid, succinic acid, glucuronic acid, phosphoric acid, glycine, lysine, arginine, EDTA, bovine serum albumin, human serum albumin and combinations thereof. 4. The method according to claim 1, wherein the concentration of the physiologically acceptable excipient is determined by the steps of: a) measuring aggregation of said histamine releaser in a reference solution consisting essentially of said histamine releaser in a concentration at or above the critical micelle concentration in the aqueous solution; b) measuring aggregation of said histamine releaser in a comparative solution consisting essentially of said histamine releaser and a pre-selected concentration of the physiologically acceptable excipient in the aqueous solution, wherein the concentration of said histamine releaser in the comparative solution is substantially the same as the concentration of said histamine releaser in the reference solution; c) optionally repeating step b) one or more times with a comparative solution having a different pre-selected concentration of the physiologically acceptable excipient; d) identifying a concentration of physiologically acceptable excipient that is sufficient to reduce aggregation of said histamine releaser in the comparative solution by at least about 25 percent compared to aggregation of said histamine releaser in the reference solution; wherein said identified concentration of step d) is the concentration of the physiologically acceptable excipient for combining with said histamine releaser to prepare the pharmaceutical formulation. 5. A pharmaceutical formulation prepared according to claim 1. 6. The pharmaceutical formulation according to claim 5, wherein said histamine releaser is a neuromuscular blocker. 7. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is selected from the group consisting of calcium chloride, sodium sulfate, magnesium sulfate, tartaric acid, maleic acid, acetic acid, citric acid, succinic acid, glucuronic acid, phosphoric acid, glycine, lysine, arginine, EDTA, bovine serum albumin, human serum albumin and combinations thereof. 8. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is a combination of any two or more excipients selected from the group consisting of glycine, EDTA, citric acid and calcium chloride. 9. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is citric acid in a concentration of from about 15 mM to about 300 mM. 10. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is EDTA in a concentration of from about 0.02 percent to about 1 percent. 11. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is calcium chloride in a concentration of from about 15 mM to about 200 mM. 12. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is a combination of citric acid in a concentration of from about 15 mM to about 100 mM and EDTA in a concentration of from about 0.02 percent to about 1 percent. 13. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is a combination of citric acid in a concentration of from about 15 mM to about 100 mM and calcium chloride in a concentration of from about 25 mM to about 75 mM. 14. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is glycine in a concentration of from about 10 mg/mL to about 100 mg/mL. 15. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is a combination of glycine in a concentration of from about 10 mg/mL to about 100 mg/mL and EDTA in a concentration of from about 0.02 percent to about 1 percent. 16. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is a combination of glycine in a concentration of from about 10 mg/mL to about 100 mg/mL and citric acid in a concentration of from about 15mM to about 100 mM. 17. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is a combination of glycine in a concentration of from about 10 mg/mL to about 100 mg/mL, citric acid in a concentration of from about 15 mM to about 100 mM, and EDTA in a concentration of from about 0.02 percent to about 1 percent. 18. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is citric acid in a concentration of about 50 mM. 19. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is EDTA in a concentration of about 0.1 percent. 20. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is calcium chloride in a concentration of about 50 mM. 21. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is a combination of citric acid in a concentration of about 50 mM and EDTA in a concentration of about 0.1 percent. 22. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is a combination of citric acid in a concentration of about 50 mM and calcium chloride in a concentration of about 50 mM. 23. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is glycine in a concentration of about 12.5 mg/mL. 24. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is a combination of glycine in a concentration of about 12.5 mg/mL and EDTA in a concentration of about 0.1 percent. 25. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is a combination of glycine in a concentration of about 12.5 mg/mL and citric acid in a concentration of about 50 mM. 26. The pharmaceutical formulation according to claim 5, wherein the physiologically acceptable excipient is a combination of glycine in a concentration of about 12.5 mg/mL citric acid in a concentration of about 50 mM, and EDTA in a concentration of about 0.1 percent. 27. The pharmaceutical formulation according to claim 5, further comprising a physiologically acceptable diluent. 28. The pharmaceutical formulation according to claim 5, wherein said formulation has a pH of from about 2 to about 8. 29. A method of suppressing pharmaceutically-induced histamine release in an animal being treated with the histamine releaser, said method comprising administering to said animal the pharmaceutical formulation according to claim 5. 30. The method according to claim 29, wherein said step of administering the pharmaceutical formulation comprises intravenously administering the pharmaceutical formulation. 31. A method for preventing cardiovascular and respiratory effects mediated by pharmaceutically-induced histamine release in an animal being treated with the histamine releaser, said method comprising administering to said animal the pharmaceutical formulation according to claim 5. 32. The method according to claim 31, wherein said cardiovascular and respiratory effects mediated by pharmaceutically-induced histamine release are selected from the group consisting of flushing, hypotension, tachycardia, bronchoconstriction, anaphylactoid reactions and anaphylactic shock, and combinations of any two or more thereof.

Details for Patent 6,911,455

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2040-01-28